Aiwen Wang

Aiwen Wang

Auto-generated profile, based on publicly available information

Aiwen Wang

Department of Pharmacy and Pharmaceutical Science, Faculty of Science National University of Singapore Singapore City Singapore

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Journal of the American Pharmacists Association
Verified
Journal Article
Closed access
JCJin Jian Chong
Jin Jian Chong
YTYan Zhi Tan
Yan Zhi Tan
LCLita Sui Tjien Chew
Lita Sui Tjien Chew
KTKok Hian Tan
Kok Hian Tan
AWAiwen Wang
Aiwen Wang

31 October 2021 in JACCP: Journal of the American College of Clinical Pharmacy
Verified
Journal Article
Closed access
PDF file
YTYan Zhi Tan
Yan Zhi Tan
JCJin Jian Chong
Jin Jian Chong
LCLita Sui Tjien Chew
Lita Sui Tjien Chew
KTKok Hian Tan
Kok Hian Tan
AWAiwen Wang
Aiwen Wang

1 May 2022 in Proceedings of Singapore Healthcare
Verified
Journal Article
Open access
RTReanne Tang
Reanne Tang
OFOuyuan Feng
Ouyuan Feng
JCJin Jian Chong
Jin Jian Chong
AWAiwen Wang
Aiwen Wang
Background: Burnout has been prevalent among healthcare workers (HCWs). However, the effect of the Coronavirus Disease (COVID-19) pandemic on this phenomenon in HCWs is unclear. Objective: This systematic review aims to evaluate the impact of COVID-19 on burnout of HCWs using Maslach Burnout Inventory (MBI). Methods: A systematic search was performed on PubMed database for articles published between 1 December 2019 and 30 June 2021. Search strategy combined terms for HCWs, COVID-19, burnout, and MBI. The main outcome of interest was burnout, including both mean prevalence and MBI scores for high emotional exhaustion (EE), high depersonalisation (DP) and low personal accomplishment (PA). Results: Four cohort studies, 90 cross-sectional studies and one randomised-controlled trial were included for review. Only one cohort study compared burnout data among HCWs before and during COVID-19. It reported a statistically significant increase in mean EE and PA scores from 21.9 to 24.8 ( p = .001), and 42.7 to 48.7 ( p = .001), respectively. The remaining studies only evaluated burnout data during COVID-19 but were missing burnout data prior to the pandemic for comparison. Across these studies, the overall mean prevalence of burnout among HCWs was 39.95%, with mean MBI EE scores of 22.07, DP scores of 7.83, and PA scores of 32.53. Burnout outcomes were generally comparable across specific healthcare professions such as doctors and nurses. Conclusion: Whilst quality research elucidating the effect of pandemic on burnout is lacking, current burnout prevalence among HCWs during COVID-19 is notable.

13 March 2026 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Open access
PDF file
AHAlfred Zheng Ting Ho
Alfred Zheng Ting Ho
JLJeren Zheng Feng Law
Jeren Zheng Feng Law
AWAiwen Wang
Aiwen Wang
DLDaniel Yan Zheng Lim
Daniel Yan Zheng Lim
JOJasmine Chiat Ling Ong
Jasmine Chiat Ling Ong
Background: Large language models (LLMs) can support clinical decision‐making by parsing databases and extracting relevant information. However, evaluating drug‐induced liver injury (DILI) often requires processing lengthy clinical histories alongside reference materials like LiverTox, which can exceed context lengths of conventional LLMs. Challenges such as information truncation hinder standard approaches like prompt engineering and retrieval‐augmented generation (RAG). To address these limitations, this study introduces DILIConsult, an agentic LLM pipeline based on GPT‐4, designed to intelligently parse clinical and drug information. Methods: To develop DILIConsult, we compared GPT‐4‐Turbo versus GPT‐4o for extracting DILI characteristics from LiverTox descriptions. We tested two approaches to analyzing cases of suspected DILI: full‐length case analysis versus sequential drug‐specific evaluations. We evaluated DILIConsult on cases of suspected DILI identified from the open source Medical Information Mart for Intensive Care‐IV (MIMIC‐IV) ICU dataset based on American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of the Liver (EASL) criteria. Outputs from DILIConsult were compared against a panel of clinicians comprising an ICU pharmacist, an ICU junior attending physician, and an ICU resident. Responses were evaluated by two senior ICU attending physicians. Results: Using GPT‐4o and a sequential approach demonstrated improved performance in the extraction of DILI characteristics and analysis of suspected DILI. DILIConsult achieved the best mean rank of 1.66 ± 0.75 in knowledge recall and ranked second for reasoning (2.00 ± 0.64) and reflection of current medical consensus (2.05 ± 0.62). DILIConsult ranked last with mean ranks of 2.07 ± 0.52 and 2.09 ± 0.72 for less omission of important information and content inaccuracy, respectively. Conclusion: DILIConsult demonstrates the potential of LLMs to assist clinicians in evaluating DILI. The findings emphasize the importance of task division in LLM‐driven workflows to minimize information loss.

10 September 2024
Verified
Preprint
Open access
AWAiwen Wang
Aiwen Wang
CMCorinne Tham Rui Min
Corinne Tham Rui Min
LTLi Ying Toh
Li Ying Toh
EAEng Teng Ang
Eng Teng Ang
OFOuyuan Feng
Ouyuan Feng
Background: Cyclooxygenase-2 (COX-2) inhibitors have different chemical structures compared to non-selective NSAIDs and are highly selective for COX-2 enzymes. There are reports of patients with prior NSAID allergy that tolerated COX-2 inhibitors, however data is heterogenous. This review aims to summarise the cross-reactivity rates of COX-2 inhibitors in patients with prior NSAID hypersensitivity in current literature. Methods: Searches were conducted in PubMed and Embase to retrieve English studies on adults with previous NSAID allergy, and had received at least one dose of celecoxib, etoricoxib, or parecoxib. Forty-eight included studies were further divided into 74 sub-studies, with a total of 1,991 patients and 2,546 challenges. Results: Overall risk of allergic reactions to COX-2 inhibitors in patients with previous allergic reactions to NSAIDs was 4.75%, with the lowest reported risk in patients with immunologic-mediated reactions to NSAIDs (2.17%). Higher risk of allergic reactions to celecoxib (6.51%) were observed compared to etoricoxib (3.21%). Most allergic reactions observed were mild. Conclusion: COX-2 inhibitor cross-reactivity is heterogenous across different patient populations with different type of NSAID hypersensitivity. In patients with prior NSAID allergy, careful history taking and discussion of risks with patient is advisable before conducting a challenge with COX-2 inhibitors.

1 October 2026 in Research in Social and Administrative Pharmacy
Verified
Journal Article
Closed access
FNFelicia Xue En Ng
Felicia Xue En Ng
YCYi Yan Chng
Yi Yan Chng
AWAiwen Wang
Aiwen Wang
BCBrandon Wen Bing Chua
Brandon Wen Bing Chua